MarketPulse

continuous glucose monitoring

14 articles
Investing.comInvesting.com··Nathan Reiff

DexCom Surges on Strong Earnings, Analyst Confidence as CGM Market Expands

DexCom beats Q1 earnings with $1.2B revenue, boasts 20 Buy ratings. New products and margin expansion drive 40% upside potential.
MDTDXCMmanufacturing expansionanalyst-ratings
Investing.comInvesting.com··David Wagner

Nine Stocks Poised to Defy 'Sell in May' as Market Hits New Highs

Record earnings beats and 27% growth challenge the 'Sell in May' strategy in 2026, with selective stock opportunities offering upside potential despite geopolitical risks.
DXCMRMDstock markethealthcare stocks
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Laboratories Stock Slumps 30%; Analysts Eye Dividend King Opportunity

Abbott Laboratories ($ABT) slides 30% amid slower nutrition and diagnostics growth, but Dividend King status and $21B Exact Sciences deal attract value investors.
ABThealthcarelong-term investing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Senseonics Raises $80M to Fund Eversense 365 Launch and Pipeline Expansion

Senseonics raises $80M through common stock and pre-funded warrant offering to fund Eversense 365 launch and pipeline development, closing May 4, 2026.
SENSpublic offeringcapital raise
BenzingaBenzinga··Usa News Group

Medtech Giants Race to Acquire AI Diagnostics as Hospital Demand Surges

Medtech giants aggressively acquiring AI diagnostic platforms as hospital adoption surges. $2.20B market projected by 2026 with 34.8% growth through 2033.
MDTDHRDXCMPROFAI diagnosticsclinical validation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CGM Market Booming in Middle East and Africa: 168% Growth Projected by 2034

Middle East and Africa CGM market projected to reach USD 855.30 million by 2034 from USD 320.44 million in 2025, growing at 11.53% CAGR.
MDTABTDXCMSENShealthcare technologymarket forecast
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Senseonics Expands European Footprint With Eversense 365, Doubling CGM Sensor Lifespan

Senseonics launches Eversense 365 implantable glucose monitor in Europe with one-year lifespan. Q4 revenue surged 72% year-over-year to $14.3 million.
SENSEuropean expansionmedical device
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom's Glucose Monitors Poised to Win Regardless of Weight-Loss Drug Champion

DexCom benefits from GLP-1 weight-loss drug adoption regardless of pharmaceutical winner, leveraging competitive moats in CGM technology and ecosystem integration.
LLYNVODXCMweight loss drugsnetwork effects
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott vs. Dexcom: Which CGM Leader Offers Better Value in 2024?

Abbott offers diversified healthcare exposure with dividend income; Dexcom provides pure CGM growth but faces GLP-1 drug competition and concentration risk.
ABTDXCMdividend stockshealthcare stocks
BenzingaBenzinga··Equity Insider

AI and Remote Care Transform MedTech: A Shift to Scalable, Outpatient-First Healthcare

Healthcare pivots toward outpatient services as AI diagnostics and remote monitoring technologies gain traction. Multiple medtech firms advance innovative solutions addressing cost and accessibility.
LIVNCLOVMBOTSENSValue-Based CareAI diagnostics
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Abbott Labs Stock Slides 22% on Weak Diagnostics, But Dividend Investors See Opportunity

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.
ABTEXAShealthcaredividend stock
GlobeNewswire Inc.GlobeNewswire Inc.··Senseonics Holdings, Inc.

Senseonics' Eversense 365 Proves Durable: Real-World Data Shows 94% Wear Rate, Strong Glucose Control

Senseonics reports real-world data from 5,059 Eversense 365 CGM users showing 93.8% wear time and strong glucose control metrics over one year.
SENSmedical devicediabetes management
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Surgical Robots and Glucose Monitors Positioned for Decade-Long Growth Despite Competition

Intuitive Surgical and DexCom positioned for long-term growth despite near-term competition, driven by aging populations and untapped market opportunities.
MDTDXCMISRGlong-term investinggrowth stocks
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes